# OrphanCure Full Pipeline Report: repodb_3ab2a1d014ffd529

- Drug: Cisplatin
- Disease: Non-Small Cell Lung Carcinoma
- Mode: no_verifier
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "Medium",
      "summary": "Cisplatin is a standard chemotherapy agent for non-small cell lung carcinoma (NSCLC), but resistance is a significant clinical challenge. Several studies explore mechanisms to overcome cisplatin resistance in NSCLC, including targeting specific signaling pathways and microRNAs. While direct evidence for repurposing cisplatin *for* NSCLC is limited as it's already a standard treatment, research focuses on enhancing its efficacy.",
      "evidence_counts": {
        "total_papers": 60,
        "supporting": 19,
        "contradicting": 2,
        "inconclusive": 39
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose CISPLATIN for non-small cell lung carcinoma",
      "drug": {
        "id": "CHEMBL11359",
        "name": "CISPLATIN",
        "aliases": [
          "cis-diamminedichloroplatinum(II)",
          "DDP",
          "cis-DDP",
          "CDDP",
          "Platinol"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "EFO_0003060",
        "name": "non-small cell lung carcinoma",
        "aliases": [
          "NSCLC",
          "non-small cell lung cancer",
          "carcinoma of lung, non-small cell",
          "lung carcinoma, non-small cell",
          "non-small cell cancer of lung"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 60,
      "polarity": {
        "supports": 19,
        "contradicts": 2,
        "inconclusive": 39
      },
      "support_ratio": "19 of 60 retrieved papers support the hypothesis",
      "queries_used": 10,
      "top_papers": [
        {
          "pmid": "35346827",
          "title": "Bisdemethoxycurcumin sensitizes the response of cisplatin resistant non-small cell lung carcinoma cell lines by activating apoptosis and autophagy.",
          "year": "2022",
          "relevance_score": 10.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent",
            "Title Match"
          ]
        },
        {
          "pmid": "32104235",
          "title": "MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1.",
          "year": "2020",
          "relevance_score": 9.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "29243778",
          "title": "Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.",
          "year": "2017",
          "relevance_score": 9.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "26396665",
          "title": "Tumstatin 185-191 increases the sensitivity of non-small cell lung carcinoma cells to cisplatin by blocking proliferation, promoting apoptosis and inhibiting Akt activation.",
          "year": "2015",
          "relevance_score": 9.5,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Title Match"
          ]
        },
        {
          "pmid": "38587027",
          "title": "miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.",
          "year": "2024",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "32407216",
          "title": "Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.",
          "year": "2020",
          "relevance_score": 9.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "33461544",
          "title": "Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells.",
          "year": "2021",
          "relevance_score": 8.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Title Match"
          ]
        },
        {
          "pmid": "38329819",
          "title": "Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance.",
          "year": "2024",
          "relevance_score": 8.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "31897216",
          "title": "AFAP1-AS1 induces cisplatin resistance in non-small cell lung cancer through PI3K/AKT pathway.",
          "year": "2020",
          "relevance_score": 8.0,
          "polarity": "SUPPORTS",
          "match_reasons": []
        },
        {
          "pmid": "40389113",
          "title": "Heme oxygenase 1 (HO-1) is a drug target for reversing cisplatin resistance in non-small cell lung cancer.",
          "year": "2026",
          "relevance_score": 8.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 1,
      "claims": [
        {
          "claim_id": "CTR-e04be1",
          "statement": "Acquired radiation resistance in NSCLC can induce thiol-dependent cisplatin cross-resistance.",
          "evidence_count": 1
        }
      ]
    },
    "7_confidence_assessment": {
      "overall": "Medium",
      "dimensions": {
        "mechanistic_strength": "High",
        "literature_strength": "Medium",
        "clinical_evidence": "Medium"
      },
      "quality_scorecard": {
        "overall_score": 0.892,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "3/3 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "8 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.333,
            "reason": "1/3 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.8,
            "reason": "Contradictory evidence discussed"
          },
          "traceability": {
            "score": 1.0,
            "reason": "3/3 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "The studies focus on sensitizing *resistant* cells, implying cisplatin is already in use.",
        "Development of resistance to cisplatin is a major clinical challenge.",
        "Cisplatin is a known chemotherapeutic with significant toxicity."
      ],
      "limitations": [
        "The provided literature primarily focuses on overcoming cisplatin resistance rather than repurposing cisplatin for NSCLC, as it is already an established treatment.",
        "Most studies are in vitro or preclinical, lacking direct clinical validation for novel repurposing strategies.",
        "The 'inconclusive' and 'contradicting' papers are not detailed, limiting a full understanding of opposing viewpoints."
      ],
      "missing_data": [
        "Direct clinical trial data specifically for repurposing cisplatin for NSCLC (as it's already a standard treatment).",
        "Detailed information on the specific targets and pathways involved in cisplatin resistance beyond those mentioned in the abstracts.",
        "Data on the efficacy of cisplatin in different subtypes or stages of NSCLC, especially in the context of emerging resistance."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Investigate combination therapies that target pathways identified in mechanistic studies (e.g., ERK, Akt, miR-103a-3p, miR-29b-3p) to enhance cisplatin efficacy in NSCLC.",
        "Conduct clinical trials evaluating novel agents in combination with cisplatin for NSCLC, particularly in patients with known resistance mechanisms.",
        "Explore strategies to overcome acquired cisplatin resistance, such as those related to radiation resistance."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 3,
      "claims": [
        {
          "claim_id": "CLM-809505",
          "statement": "Cisplatin resistance in NSCLC can be sensitized by modulating specific molecular targets.",
          "confidence_numeric": 0.8,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [
            "ERK",
            "Akt",
            "miR-103a-3p",
            "miR-29b-3p",
            "VEGF",
            "Nrf2",
            "HO-1",
            "Tie1",
            "HIF-1\u03b1"
          ],
          "citation_count": 6,
          "risk_flags": []
        },
        {
          "claim_id": "CLM-793902",
          "statement": "Cisplatin is used in combination chemotherapy regimens for resected non-small cell lung cancer.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 1,
          "risk_flags": []
        },
        {
          "claim_id": "CTR-e04be1",
          "statement": "Acquired radiation resistance in NSCLC can induce thiol-dependent cisplatin cross-resistance.",
          "confidence_numeric": 0.5,
          "confidence_label": "MEDIUM",
          "polarity": "CONTRADICTS",
          "verification_status": "UNVERIFIED",
          "targets": [],
          "citation_count": 1,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 3,
      "entries": [
        {
          "claim_id": "CLM-809505",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "6f1f0adb908d",
          "timestamp": "2026-06-03T14:31:30.737564+00:00",
          "paper_evidence": [
            {
              "pmid": "35346827",
              "snippet": "Bisdemethoxycurcumin sensitizes the response of cisplatin resistant non-small cell lung carcinoma cell lines by activating apoptosis and autophagy.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "32104235",
              "snippet": "MicroRNA-103a-3p potentiates chemoresistance to cisplatin in non-small cell lung carcinoma by targeting neurofibromatosis 1.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "29243778",
              "snippet": "Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "26396665",
              "snippet": "Tumstatin 185-191 increases the sensitivity of non-small cell lung carcinoma cells to cisplatin by blocking proliferation, promoting apoptosis and inhibiting Akt activation.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "38587027",
              "snippet": "miR-29b-3p targetedly regulates VEGF to inhibit tumor progression and cisplatin resistance through Nrf2/HO-1 signaling pathway in non-small cell lung cancer.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            },
            {
              "pmid": "33461544",
              "snippet": "Hypoxia-induced Tie1 drives stemness and cisplatin resistance in non-small cell lung carcinoma cells.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CLM-793902",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "6f1f0adb908d",
          "timestamp": "2026-06-03T14:31:30.737564+00:00",
          "paper_evidence": [
            {
              "pmid": "32407216",
              "snippet": "Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.",
              "polarity": "SUPPORTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CTR-e04be1",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "6f1f0adb908d",
          "timestamp": "2026-06-03T14:31:30.737564+00:00",
          "paper_evidence": [
            {
              "pmid": "38329819",
              "snippet": "Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance.",
              "polarity": "CONTRADICTS",
              "verification": "UNVERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 0
        }
      ]
    }
  },
  "metadata": {
    "run_id": "6f1f0adb908d",
    "created_at": "2026-06-03T14:31:09.080349+00:00",
    "drug": "CISPLATIN",
    "disease": "non-small cell lung carcinoma",
    "total_claims": 3,
    "quality_score": 0.8916666666666667,
    "reruns": 0
  }
}
```
